Selective Estrogen Receptor Modulator Clinical Trial
Official title:
Comparison of the Clinical Efficacy and Safety Between Raloxifene and Bazedoxifene in Postmenopausal Women.
Although there are two kinds of selective estrogen receptor modulator (SERM) :raloxifene (RLX) and bazedoxifene (BZA), the difference is still unclear. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.
Selective estrogen receptor modulator (SERM) is an important option for postmenopausal
osteoporosis. There are two SERM approved in Japan for the treatment of postmenopausal
osteoporosis in women at increased risk of fracture. One is raloxifene (RLX), and the other
is bazedoxifene (BZA). There are few reports concerning to the clinical efficacy and safety
data. In this study, we plan to compare clinical efficacy and safety between RLX and BZA.
The main objective of this study is to reveal the effects of RLX and BZA on bone mineral
density, bone turnover markers, and bone quality markers.
;
Observational Model: Case Control, Time Perspective: Prospective